Last reviewed · How we verify
Articaine chloride 4% with epinephrine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Articaine chloride 4% with epinephrine (Articaine chloride 4% with epinephrine) — Mahmoud Ahmed Mahmoud.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Articaine chloride 4% with epinephrine TARGET | Articaine chloride 4% with epinephrine | Mahmoud Ahmed Mahmoud | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Articaine chloride 4% with epinephrine CI watch — RSS
- Articaine chloride 4% with epinephrine CI watch — Atom
- Articaine chloride 4% with epinephrine CI watch — JSON
- Articaine chloride 4% with epinephrine alone — RSS
Cite this brief
Drug Landscape (2026). Articaine chloride 4% with epinephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/articaine-chloride-4-with-epinephrine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab